United Therapeutics Corporation

UTHR

US91307C1027

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 17:32:22 17/07/2024 BST			5-day change	1st Jan Change
334.5 ^USD	+1.94%		+1.56%	+52.06%

07-11	TD Cowen Adjusts Price Target on United Therapeutics to $350 From $270, Maintains Buy Rating	MT
07-11	Everything's going according to plan

Corsair Pharma, Inc. announced that it has received funding from United Therapeutics Corporation

January 02, 2018

Corsair Pharma, Inc. entered into a purchase agreement for a minority stake investment from new investor United Therapeutics Corporation (NasdaqGS:UTHR) on January 3, 2017.

Latest news about United Therapeutics Corporation

TD Cowen Adjusts Price Target on United Therapeutics to $350 From $270, Maintains Buy Rating	07-11	MT
Everything's going according to plan	07-11
Morgan Stanley Downgrades United Therapeutics to Equalweight From Overweight, Adjusts PT to $321 From $310	07-11	MT
Analyst recommendations: Albemarle, Levi Strauss & Co, On Semiconductor, Spotify, Costco...	07-11
United Therapeutics Says Idiopathic Pulmonary Fibrosis Treatment Study Reaches Full Enrollment	07-10	MT
United Therapeutics Corporation Announces Full Enrollment of the TETON 2 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis	07-10	CI
UBS Adjusts Price Target on United Therapeutics to $370 From $300, Maintains Buy Rating	07-08	MT
United Therapeutics Corporation(NasdaqGS:UTHR) added to Russell 1000 Defensive Index	06-30	CI
United Therapeutics Corporation(NasdaqGS:UTHR) added to Russell 1000 Value-Defensive Index	06-30	CI
United Therapeutics Insider Sold Shares Worth $2,395,035, According to a Recent SEC Filing	06-28	MT
United Therapeutics Insider Sold Shares Worth $2,285,941, According to a Recent SEC Filing	06-28	MT
United Therapeutics Corporation Announces Board Changes	06-27	CI
Tempus, United Therapeutics Launch Collaboration to Use AI to Detect Risk of Pulmonary Hypertension	06-25	MT
Tempus AI, Inc. Announces Collaboration with United Therapeutics to Study Use of AI to Detect Patients at Risk for Pulmonary Hypertension	06-25	CI
United Therapeutics Insider Sold Shares Worth $1,033,984, According to a Recent SEC Filing	06-17	MT
United Therapeutics Insider Sold Shares Worth $1,027,716, According to a Recent SEC Filing	06-14	MT
Transcript : United Therapeutics Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 04:00 PM	06-12
Wells Fargo Raises Price Target on United Therapeutics to $350 From $325, Maintains Overweight Rating	06-12	MT
Liquidia's Yutrepia Launch Cleared as Court Denies Injunction	06-03	MT
United Therapeutics Insider Sold Shares Worth $545,800, According to a Recent SEC Filing	05-16	MT
United Therapeutics Insider Sold Shares Worth $1,911,532, According to a Recent SEC Filing	05-14	MT
United Therapeutics Insider Sold Shares Worth $1,898,393, According to a Recent SEC Filing	05-10	MT
United Therapeutics Insider Sold Shares Worth $949,737, According to a Recent SEC Filing	05-08	MT
United Therapeutics Insider Sold Shares Worth $1,871,233, According to a Recent SEC Filing	05-07	MT
United Therapeutics Insider Sold Shares Worth $2,585,601, According to a Recent SEC Filing	05-06	MT

Chart United Therapeutics Corporation

Duration

Period

More charts

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKindâs Afrezza (insulin human) Inhalation Powder.

Sector

Biotechnology & Medical Research

Calendar

30/07/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for United Therapeutics Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

328.2 USD

Average target price

314.5 USD

Spread / Average Target

-4.18%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
UNITED THERAPEUTICS CORPORATION	+52.06%	14.56B
MODERNA, INC.	+22.10%	47.96B
IQVIA HOLDINGS INC.	+0.72%	42.45B
LONZA GROUP AG	+43.96%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+26.30%	31.6B
ICON PUBLIC LIMITED COMPANY	+20.85%	28.63B
CELLTRION, INC.	-4.47%	28.03B
MEDPACE HOLDINGS, INC.	+44.93%	14.14B
BIO-TECHNE CORPORATION	+2.73%	12.58B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.67%	11.71B

Other Biotechnology & Medical Research

United Therapeutics Corporation

Equities

UTHR

US91307C1027

Biotechnology & Medical Research

Corsair Pharma, Inc. announced that it has received funding from United Therapeutics Corporation

Latest news about United Therapeutics Corporation

Chart United Therapeutics Corporation

Company Profile

Income Statement Evolution

Ratings for United Therapeutics Corporation

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research